Supporting treatment adherence for resilience and thriving (START). A mhealth intervention to improve ART adherence for HIV-positive stimulant-using men. With aims to improve VL suppression at 6 months (primary outcome) and determine whether any gains are maintained at month 12 (secondary outcome). Optimizing treatment as prevention (TasP) with HIV-positive stimulant-using men who have sex with men (HIV+ SUMSM) is among the highest priorities of NIH and the National HIV/AIDS Strategy as this population is at elevated risk for transmitting HIV and experiencing faster clinical HIV progression.

Grant Title: The START Study: An mHealth Intervention to Improve ART Adherence Among Geographically Dispersed Stimulant-using HIV-Positive Men, R01DA049843.